Victory Capital Management
HRTX icon

Victory Capital Management’s Heron Therapeutics HRTX Stock Holding History

Victory Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Buy
21,233
+319
+2% +$370 ﹤0.01% 2380
2025
Q4 		$27.2K Buy
20,914
+29
+0.1% +$36 ﹤0.01% 2369
2025
Q3 		$26.3K Buy
20,885
+2,863
+16% +$4.54K ﹤0.01% 2383
2025
Q2 		$37.3K Sell
18,022
-187
-1% -$382 ﹤0.01% 2406
2025
Q1 		$40.1K Sell
18,209
-471
-3% -$914 ﹤0.01% 2385
2024
Q4 		$28.6K Buy
18,680
+398
+2% +$645 ﹤0.01% 2429
2024
Q3 		$36.4K Buy
18,282
+270
+1% +$645 ﹤0.01% 2410
2024
Q2 		$63K Sell
18,012
-750
-4% -$2.3K ﹤0.01% 2344
2024
Q1 		$52K Sell
18,762
-1,167
-6% -$2.93K ﹤0.01% 2375
2023
Q4 		$33.9K Buy
19,929
+4,617
+30% +$5.08K ﹤0.01% 2473
2023
Q3 		$15.8K Buy
15,312
+2,424
+19% +$3.45K ﹤0.01% 2461
2023
Q2 		$14.9K Sell
12,888
-299
-2% -$533 ﹤0.01% 2465
2023
Q1 		$19.9K Sell
13,187
-171
-1% -$428 ﹤0.01% 2509
2022
Q4 		$33.4K Buy
13,358
+1,705
+15% +$5.49K ﹤0.01% 2485
2022
Q3 		$49K Sell
11,653
-1,161
-9% -$4.54K ﹤0.01% 2568
2022
Q2 		$36K Sell
12,814
-44
-0.3% -$177 ﹤0.01% 2578
2022
Q1 		$58K Sell
12,858
-1,081
-8% -$7.91K ﹤0.01% 2583
2021
Q4 		$127K Sell
13,939
-430
-3% -$4.39K ﹤0.01% 2544
2021
Q3 		$154K Sell
14,369
-714
-5% -$8.69K ﹤0.01% 2569
2021
Q2 		$234K Buy
15,083
+1,125
+8% +$17.9K ﹤0.01% 2495
2021
Q1 		$226K Sell
13,958
-349
-2% -$6.22K ﹤0.01% 2497
2020
Q4 		$303K Buy
14,307
+730
+5% +$12.7K ﹤0.01% 2281
2020
Q3 		$201K Buy
+13,577
New +$212K ﹤0.01% 2286

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Victory Capital Management's HRTX Position: Q1 2026 in Review

Victory Capital Management increased its Heron Therapeutics (HRTX) stake by 1.5% in Q1 2026, buying an estimated $370 and bringing the position to 21,233 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Victory Capital Management first reported a position in HRTX in Q3 2020 and has held it in 23 quarters since. The position peaked at $303K in Q4 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Victory Capital Management held 21,233 shares of Heron Therapeutics worth $17K as of Q1 2026.
  • Victory Capital Management bought 319 Heron Therapeutics shares in Q1 2026, an estimated $370.
  • Heron Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2380 holding.
  • Victory Capital Management first reported a position in Heron Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Victory Capital Management's Heron Therapeutics position peaked at $303K in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.